Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil

OBJECTIVES: In Brazil, imatinib mesylate is supplied as the first-line therapy for chronic myeloid leukemia in the chronic phase through the public universal healthcare program, Sistema Único de Saúde (SUS). We studied the socio-demographic factors that influenced therapy success in a population in...

Descripción completa

Detalles Bibliográficos
Autores principales: Rego, Monica Napoleão Fortes, Metze, Konradin, Lorand-Metze, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449460/
https://www.ncbi.nlm.nih.gov/pubmed/26039947
http://dx.doi.org/10.6061/clinics/2015(05)03